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Abstract
Background: Circulating microRNAs (miRNAs) in exosomes are emerging as clinically
useful tools for cancer detection. However, little is known about their diagnostic impact
in clear-cell renal cell carcinoma (ccRCC).
Objective: To investigate whether miRNAs in serum exosomes can serve as biomarkers
in ccRCC.
Design, setting, and participants: Serum samples were obtained from 82 patients with
ccRCC and 80 healthy volunteers. Exosomes were extracted and puriﬁed to selectively
capture exosomes positive for tumor-associated epithelial cell adhesion molecule
(EpCAM) via a magnetic bead technique. Total RNA was extracted and expression levels
of miR-210, miR-1233, and miR-15a miRNAs were quantiﬁed and normalized to U6
levels.
Outcome measurements and statistical analysis: Expression levels were compared
using a Mann-Whitney U-test, Friedman test, or Wilcoxon test. Receiver operating
characteristic (ROC) curves were plotted to assess the diagnostic value of exosomal
miRNAs for differentiation between ccRCC patients and controls.
Results and limitations: Expression levels of exosomal miR-210 and miR-1233 were
signiﬁcantly higher in ccRCC patients than in healthy individuals (both p < 0.01). No
signiﬁcant difference was observed for exosomal miR-15a. Exosomal miR-210 and miR-
1233 expression levels in different TNM stages were signiﬁcantly higher than in the
controls (all p < 0.01). Exosomal miR-210 and miR-1233 expression levels were signiﬁ-
cantly lower in postoperative than in preoperative samples (both p < 0.01). ROC analysis
demonstrated that exosomal expression levels distinguished ccRCC patients from
healthy individuals with 70% sensitivity and 62.2% speciﬁcity for miR-210, and 81%
sensitivity and 76% speciﬁcity for miR-1233. The retrospective design and lack of other
tumor subtypes are limitations of the study.
Conclusions: Serum exosomal miRNAs might represent potential diagnostic biomarkers
in ccRCC in the future.
Patient summary: Circulating levels of exosomal microRNAs miR-210 and miR-1233
have potential as biomarkers for diagnostic and monitoring purposes in renal cancer in
the future. These molecules can be measured in serum in so-called liquid biopsy.
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Kidney cancer currently represents the third most common
urological cancer in the USA, with an estimated 61560 new
cases and 14 080 deaths in 2015 [1]. Clear-cell or
conventional renal cell carcinoma (ccRCC) is the most
frequent RCC subtype, accounting for approximately 75–
80% of these tumors, and is responsible for the majority of
deaths caused by the disease [2]. Recent advances in
diagnostic techniques have increased early ccRCC detection
and decreased the mortality rate. However, up to 30% of
patients with ccRCC present with metastatic disease at
diagnosis, and nearly 20–30% of patients undergoing
surgery will suffer recurrence [3]. Despite longer survival
and improved response rates to targeted therapy for
metastatic RCC, median overall survival is still <2 yr
[4]. Therefore, it is highly desirable to have biomarkers
suitable for ccRCC screening and monitoring.
Liquid biopsy testing of circulating tumor DNA or tumor
cells has been considered the most promising tool for
clinical application, although the majority of circulating
tumor DNA is often not of cancerous origin and circulating
tumor cells are detected incidentally [5,6]. RNAs transcribed
from noncoding regions are arbitrarily classified as either
short or long noncoding RNAs using a threshold of
200 nucleotides. Short noncoding RNA comprises micro-
RNAs (miRNAs), which are regarded as small but highly
influential molecules [7]. Several studies have demonstrat-
ed that selective loading of specific proteins and miRNAs in
exosomes plays a role in cell-to-cell communication
[8,9]. Exosomes can be secreted by cancer cells during
tumor progression and metastasis [10]. Although the
secretory mechanisms and biological functions of tumor-
associated exosomes are still unclear, use of circulating
exosomes as potential noninvasive biomarkers holds
promise.
Several researchers, including our own group, recently
reported differences in miRNA expression levels in blood
samples between ccRCC patients and healthy controls [11–
13]. It is still not known whether these miRNAs are also
expressed in tumor-associated exosomes. To address this
question, the present study had three aims: (1) to extract
and purify tumor-associated epithelial cell adhesion mole-
cule (EpCAM)-positive exosomes; (2) to confirm whether
circulating exosomal miRNA is stable enough for amplifi-
cation; and (3) to evaluate expression levels of three
selected miRNAs in tumor-associated exosomes in serum
from ccRCC patients and healthy controls.
2. Patients and methods
2.1. Patients and sample collection
This retrospective analysis included data for 82 ccRCC patients who
underwent curative partial or radical nephrectomy and for whom a
blood sample was collected 1d before tumor resection at the Department
of Urology at Zhejiang Cancer Hospital in Hang Zhou. Diagnoses were
conﬁrmed by two independent genitourinary pathologists. Pathologic T
stages were uniformly adjusted according to the 7th edition of the TNMPlease cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.euclassiﬁcation system [14]. ccRCC was graded according to the Fuhrman
criteria [15]. The study was approved by the local ethics committee.
Patients received necessary information concerning the study and a
consent statement was signed by each patient. Control serum samples
were collected from 80 healthy volunteers. In addition, serum samples
were collected from ten patients 7 d after tumor resection. Details for the
study population are presented in Supplementary Table 1.
2.2. Processing of serum samples
Serum samples were obtained via centrifugation of blood samples at
1200  g (centrifuge model 5417R; Eppendorf, Hamburg, Germany) for
10 min at 4 8C to spin down the cells. The supernatant was collected and
further centrifuged at 12 000  g for 10 min at 4 8C (centrifuge model
5417R; Eppendorf) to completely remove cellular components. The cell-
free serum samples were then stored at 80 8C until exosome isolation.
Serum samples were processed and frozen within 4 h after the blood draw.
2.3. Isolation of total exosomes from serum
Exosomes were isolated using Total exosome isolation reagent
(Invitrogen, Carlsbad, CA, USA). In brief, 500 ml of serum was centrifuged
at 3000  g for 30 min to remove cells and cell debris. The supernatant
was mixed with 100 ml of exosome isolation reagent and incubated at 2–
8 8C for 30 min. The sample was then centrifuged at 10 000  g for
30 min at 4 8C. Total exosomal pellets were dissolved in SDS sample
buffer.
2.4. Exosome purification with EpCAM beads
EpCAM positive exosomes were isolated using EpCAM isolation beads
(Invitrogen) with 40 ml of beads per 100 ml of sample. After incubation
for 3 h at 4 8C under slow rotation, the bead-bound exosomes were
isolated on a magnetic separator and washed and eluted for downstream
analysis.
2.5. Flow cytometry analysis and immunofluorescence of
circulating exosomes
The beads were pelleted by centrifugation at 1000  g for 3 min at room
temperature (RT), washed twice with 1 ml of phosphate-buffered saline
(PBS)/0.5% bovine serum albumin (BSA), and the exosome-bead complex
was incubated with anti-EpCAM ﬂuorescein isothiocyanate (FITC)–
conjugated primary antibodies or corresponding isotype control
(Invitrogen) at RT for 1 h. The labeled exosome-bead complexes were
then pelleted and washed twice. The ﬁnal complexes were resuspended
in 150 ml of PBS/0.5% BSA for ﬂow cytometry analysis. Flow cytometry
was performed on a Beckman Coulter system (Brea, CA, USA). For
immunoﬂuorescence, exosome-bead complexes were incubated with
anti-CD9 antibodies conjugated to Alexa Fluor 488 (Abcam, Cambridge,
UK) at RT for 1 h and washed twice as above. Exosome-latex bead-
antibody complexes were spread onto a microscope slide and a cover slip
was paled on top and sealed with nail polish. The slides were examined
under an Olympus BX50 microscope (Tokyo, Japan) and images were
taken with an Olympus DP70 camera using Leica imaging software.
2.6. Stability of circulating exosomes
2.6.1. Delayed processing
Exosome samples were divided into two groups (n = 6 per group) for
experiments at RT and 4 8C. Each group was divided into three aliquots
for delayed processing (0, 6, and 24 h). The exosome samples were then
used for RNA extraction.rum Exosomes as Potential Biomarkers in Clear-cell Renal Cell
f.2016.09.007
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Each exosome samples was divided into three aliquots. One aliquot was
snap-frozen in liquid nitrogen and then immediately thawed at RT.
Another aliquot was snap-frozen and thawed and the thawed sample was
left at RT for 2 h. The exosome samples were then used for RNA extraction.
2.6.3. Lability of free RNA added to exosome samples
We added 1000 ng of commercially available human reference RNA
(Stratagene, San Diego, CA, USA) to randomly selected exosome samples
and incubated them for 0, 10, 20, or 30 s at RT. After incubation, QIAzol
solution (Qiagen, Hilden, Germany) was immediately added to stop any
ribonuclease activity before RNA extraction.
2.7. RNA extraction
Total RNA was extracted using a MicroMini kit (Qiagen) according to the
manufacturer’s protocol. In brief, 700 ml of QIAzol solution was added to
each sample for lysis. RNA was eluted in 25 ml of RNase-free water. TheFig. 1 – (A) Flow cytometry analysis of tumor-associated exosomes. Appropriat
Immunofluorescence staining after separation of tumor-associated exosomes c
complexes.
Please cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.euRNA concentration and purity were monitored via UV spectrophotome-
try using a Nanodrop ND-1000 instrument (Thermo Scientiﬁc, Waltham,
MA, USA). The RNA specimens were stored at 80 8C until reverse
transcription (RT) was performed.
2.8. Reverse transcription
RT reactions were carried out with a miScript reverse transcription kit
(Qiagen) in a total volume of 20 ml containing 10 ml of RNA extract, 4 ml of
5 miScript RT buffer, and 1 ml of miScript reverse transcriptase mix. For
synthesis of cDNA, the reaction mixtures were incubated at 37 8C for
60 min and 95 8C for 5 min, and then held at 4 8C. The cDNA specimens
were stored at 20 8C until polymerase chain reaction (PCR).
2.9. miRNA quantification by real-time quantitative PCR
Amounts of miRNAs were quantiﬁed by qPCR using a miScript SYBR
green PCR kit (Qiagen). A 2-ml aliquot of cDNA solution was ampliﬁede gating reveal strong intensity for the marker EpCAM. (B)
learly showed the exosome marker CD9 on the surface of exosome-bead
rum Exosomes as Potential Biomarkers in Clear-cell Renal Cell
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miScript universal primer, 1 ml of 10 miScript primer assay, and 8.5 ml
of nuclease-free water in a ﬁnal volume of 25 ml. Three miRNAs (miR-15,
miR-210, and miR-1233; Qiagen) were selected on the basis of previous
reports. Quantitative PCR was run on a 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA). The reaction mixtures were
incubated at 95 8C for 10 min, followed by 40 cycles of 95 8C for 15 s,
56 8C for 30 s, and 72 8C for 35 s. Universal human reference RNA
(Stratagene) was used as a positive control and RNase-free water
(Qiagen) as a negative control in each PCR assay. Cycle threshold (Ct)
values were calculated using SDS 1.4 software (Applied Biosystems).
Each sample was run in duplicate for analysis. Expression levels of theFig. 2 – Fig. 2. Scatter plots of expression levels of exosomal (A) miR-210, (B) m
carcinoma (ccRCC; n = 82) and healthy controls (n = 80). The exosomal miR-210
13.5ES3 W 4.6ES3) than in the controls (mean expression 1.3ES3 W 0.2ES3; p 
patients (mean expression 115.9ES3 W 30.7ES3) than in the controls (mean ex
observed for the level of exosomal miR-15a (p = 0.619). miRNA expression leve
the median value. A Mann-Whitney U-test was used to determine statistical si
Please cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.eumiRNAs were normalized to U6, and were calculated using the 2DCt
method.
2.10. Statistical analysis
Expression levels were compared using the Mann-Whitney U-test,
Friedman test, or Wilcoxon test. Receiver operating characteristics (ROC)
curves were plotted to assess the diagnostic value of exosomal miRNAs
for differentiation between ccRCC patients and controls. A p value of
<0.05 was considered statistically signiﬁcant for multiple comparisons.
All analyses were performed using SPSS version 13.0 and GraphPad
prism 5.0 software.iR-1233, and (C) miR-15 in serum from patients with clear-cell renal cell
 level was significantly higher in ccRCC patients (mean expression
< 0.001). The exosomal miR-1233 level was significantly higher in ccRCC
pression 4.5ES3 W 0.6ES3; p < 0.001). No significant difference was
ls (log10 scale on the y-axis) were normalized to U6. The line represents
gnificance.
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3.1. Flow cytometry analysis and immunostaining of
circulating tumor-associated exosomes
To separate tumor-associated exosomes, total circulating
exosomes were incubated with anti-EpCAM magnetic beads
and the tumor-associated exosomes were isolated by
magnetic separation. Tumor-associated exosomes were
then visualized following incubation with fluorescence-
conjugated antibodies to EpCAM and an isotype control
(Fig. 1A). Immunostaining of the same beads clearly showed
the exosome marker CD9 on the surface of the exosome-
bead complexes (Fig. 1B).
3.2. Effect of different conditions on circulating exosomes
Circulating tumor-associated exosomal U6 RNA (as deter-
mined by real-time quantitative PCR) revealed no differ-
ences in exosomal miRNA expression for different exposure
times and incubation temperatures (p > 0.05; Supplemen-
tary Fig. 1A). The quantity of RNA extracted (as determined
by spectrometry after various processing steps, including
freeze-thawing, 2-h storage after freeze-thawing, and no
treatment) showed no significant differences in median RNA
extracted (p > 0.05; Supplementary Fig. 1B). The quantity of
RNA extracted at 10, 20, and 30 s after addition of exogenous
RNA and without any RNA addition revealed an obvious
decrease in exogenous free RNA over time, suggesting that
free RNA added to the sample was immediately degraded by
RNA enzyme in cell-free serum and became undetectable
(p > 0.05; Supplementary Fig. 1C).
3.3. Expression levels of exosomal miR-210, miR-1233, and
miR-15 in serum
Expression levels of exosomal miR-210, miR-1233 and miR-
15 in serum were analyzed using scatter plots for
comparison of ccRCC patients (n = 82) and healthy controls
(n = 80). Both exosomal miR-210 (p < 0.001; Fig. 2A) andTable 1 – Correlation between clinical characteristics and miRNA level
Parameter Patients Exosomal miR
(n) Mean expression 
Sex 
Male 42 0.016 
Female 40 0.010 
Age: 
58 yr 41 0.012 
57 yr 41 0.009 
Stage 
T1 + T2 52 0.013 
T3 30 0.014 
Grade 
G1 + G2 62 0.014 
G3 + G4 20 0.012 
Statistical signiﬁcance set to p < 0.0125 after Bonferroni correction.
Please cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.euexosomal miR-1233 (p < 0.001; Fig. 2B) levels were
significantly higher in ccRCC patients than in controls.
There was no significant difference in exosomal miR-15a
levels (p = 0.892; Fig. 2C). We examined the correlation
between exosomal miRNA levels and clinical parameters.
We found no significant association between exosomal
miRNA levels and gender, age, or ccRCC grade (Table 1).
Next, we compared expression levels of exosomal miRNAs
between the control subjects and ccRCC patients with
different TNM stages. Exosomal miR-210 and miR-1233
expression levels in each stage were significantly higher
than in the controls (all p < 0.01; Fig. 3A,B). No significant
differences were observed among the different TNM stages.
3.4. Comparison of preoperative and postoperative serum
exosomal microRNAs in ccRCC
Expression levels of serum exosomal miR-210 and miR-
1233 were analyzed before and 7 d after surgical tumor
removal in ccRCC patients. Expression levels of exosomal
miR-210 (Fig. 4A) and exosomal miR-1233 (Fig. 4B) were
significantly lower in postoperative than in preoperative
samples.
3.5. Serum exosomal miR-210 and miR-1233 as a diagnostic
tool in ccRCC
To assess the feasibility of serum exosomal miR-210 and
miR-1233 as ccRCC diagnostic tools, we performed ROC
curve analysis. The area under the ROC curve (AUC) for
exosomal miR-210 was 0.69 (95% CI 0.61–0.77) with
sensitivity of 70% and specificity of 62.2% in discriminating
between ccRCC patients and controls (Fig. 5A). Exosomal
miR-1233 yielded an AUC of 0.82 (95% CI 0.75–0.89) with
sensitivity of 81% and specificity of 76% (Fig. 5B).
4. Discussion
Exosomes have emerged as a novel source of noninvasive
cancer biomarkers as tumor-specific molecules can bes
-210 Exosomal miR-1233
p value Mean expression p value
0.238 0.653
0.12
0.11
0.989 0.403
0.108
0.123
0.415 0.131
0.108
0.127
0.378 0.693
0.111
0.125
rum Exosomes as Potential Biomarkers in Clear-cell Renal Cell
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Fig. 3 – Scatter plots of expression levels of exosomal (A) miR-210 and (B) miR-1233 in serum from patients with clear-cell renal cell carcinoma (ccRCC)
of different TNM stages (20 with stage 1, 32 with stage 2, 30 with stage 3). Expression levels of exosomal miR-210 and miR-1233 in each stage were
significantly higher than in control individuals (both p < 0.01). No significant differences were observed between the different TNM stages. miRNA
expression levels (log10 scale on the y-axis) were normalized to U6. The lines represent median values. A Mann-Whitney U-test was used to determine
statistical significance.
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studies have examined exosomal miRNAs as potential
tumor biomarkers in attempts to improve the accuracy of
diagnostic methods [16]. Regarding urologic cancers,
circulating exosomal miR-1290 and miR-375 might serve
as sensitive biomarkers for prognostic purposes in castra-
tion-resistant prostate cancer [17]. Another study foundFig. 4 – Changes in expression levels of exosomal (A) miR-210 and (B) miR-123
n = 10) before (pre-Op) and 7 d after (post-Op) surgical tumor removal. The ex
postoperative (mean expression: 9.6ES3 W 3.2ES3) than in preoperative sampl
exosomal miR-1233 was also significantly lower in postoperative (mean expre
expression 11.4ES3 W 7ES3; p = 0.008). miRNA expression levels (log10 scale o
were determined using the Wilcoxon test.
Please cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.euthat overexpression of exosomal miRNA in urine was
associated with bladder cancer [18]. To the best of our
knowledge, this is the first study to compare expression
levels of serum exosomal miRNAs between ccRCC patients
and healthy controls. Our results indicate that circulating
exosomal miRNAs hold promise for so-called liquid biopsy
for RCC diagnosis.3 in serum from patients with clear-cell renal cell carcinoma (ccRCC;
pression level of exosomal miR-210 was significantly lower in
es (mean expression 1.3ES3 W 0.3ES3; p = 0.004). The expression level of
ssion 32.8ES3 W 15.6ES3) than in preoperative samples (mean
n the y-axis) were normalized to U6. Statistically significant differences
rum Exosomes as Potential Biomarkers in Clear-cell Renal Cell
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Fig. 5 – Receiver operating characteristic (ROC) curve analysis for
exosomal miR-210 and miR-1233 in discrimination of patients with
clear-cell renal cell carcinoma from control individuals. (A) Exosomal
miR-210 yielded an AUC (area under the ROC curve) of 0.69 (95%
confidence interval [CI] 0.61–0.77) with sensitivity of 70% and
specificity of 62.2%. (B) Exosomal miR-1233 yielded an AUC of 0.82
(95%CI 0.75–0.89) with sensitivity of 81% and specificity of 76%.
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reference gene such as U6 snRNA or 5S rRNA to normalize
expression levels [19,20]. For the Qiagen miScript PCR
system use of U6 and other snRNAs is recommended for
normalization of miRNA expression levels (www.qiagen.
com). We confirmed that serum exosomal miRNA-210 was
stable enough for amplification after prolonged storage,
freeze/thaw cycles, and RNase treatment. Among cell-free
nucleic acids, small nucleic acid fragments are more
frequently detected in body fluids, possibly because of
protection in a complex with exosomes or other vesicles
[21]. We previously reported that small RNA fragments are
abundant in urine [22]. Whether miRNAs or other small
nucleic acid cargos within exosomes can pass through the
kidney barrier into urine warrants further investigation.
We analyzed expression patterns for three exosomal
miRNAs in serum samples from 82 ccRCC patients and
80 healthy controls. All the miRNAs we obtained had good
quality for amplification. Exosomal miR-210 and miR-1233
levels were higher in ccRCC patients than in healthy
controls. The difference in serum exosomal miR-15 levels
between ccRCC patients and healthy controls was statisti-
cally nonsignificant. von Brandenstein et al [11] found thatPlease cite this article in press as: Zhang W, et al. MicroRNAs in Se
Carcinoma. Eur Urol Focus (2016), http://dx.doi.org/10.1016/j.eumiRNA-15a levels from paraffin-embedded tissue samples
and urine samples could differentiate malignant and benign
samples. Taken together, these data suggest that not all
overexpressed miRNAs can be loaded into secreted exo-
somes.
Wong et al [23] reported increased miR-1233 levels in
patients with heart failure. Increased miR-210 levels have
also been reported in the context of various cancers and
other hypoxia-induced pathologic conditions [24,25]. miR-
NAs are expressed in all organisms, which could influence
the diagnostic accuracy. Chevillet et al [26] quantified both
the number of exosomes and the number of miRNA
molecules in an exosome collection, and found that most
exosomes did not harbor many copies of miRNA molecules.
Exosomes can reflect their tissue or cell of origin by the
presence of specific surface proteins [27]. We used magnetic
beads bound to EpCAM antibodies to avoid secondary
interference from nonepithelial tissues such as heart, which
might improve the accuracy of ccRCC detection.
Exosomal miR-210 and miR1233 levels were significant-
ly higher in patients with TNM stage 1 ccRCC and other
stages compared to healthy controls (p < 0.01), but there
were no differences among the different stages. We also
compared preoperative and postoperative expression
levels. Expression levels of miR-210 (p = 0.004) and miR-
1233 (p = 0.008) were significantly lower postoperatively,
suggesting that both miR-210 and miR-1233 might be
released to some extent from the renal primary tumor into
serum, and that miRNA changes might directly reflect
cancer status. ROC analysis showed that serum exosomal
miR-210 and miR-1233 levels can differentiate ccRCC
patients from healthy controls.
Although this study was conducted according to the
reporting recommendations for tumor marker prognostic
studies [28], some limitations merit discussion. The sample
size of our study cohort was relatively small, so further
validation in larger patient cohorts is necessary. Owing to
the enormous heterogeneity of renal neoplasms, it is highly
unlikely that a single molecule would be ideal for evaluation
and diagnostic purposes. The retrospective design is another
limitation. We plan to validate our results in a prospective
study in the future. In the present study, we did not evaluate
exosomal miRNA expression levels in other renal neoplasm
subtypes. Although ccRCC is considered the most common
renal neoplasm, it will be interesting to investigate
expression patterns for exosomal miRNAs in other renal
neoplasm subtypes. Despite these limitations, our study
clearly demonstrates that miRNA-containing exosomes in
serum from ccRCC patients are stable enough to be
amplified, and thus might serve as a novel source of RCC
biomarkers in the future.
5. Conclusions
Serum exosomal miR-210 and miR-1233 were upregulated
in ccRCC independently of clinical staging. Circulating
exosomal miR-210 as well as miR-1233 might be poten-
tially used in ‘liquid biopsies’ for diagnostic and monitoring
purposes in RCC patients.rum Exosomes as Potential Biomarkers in Clear-cell Renal Cell
f.2016.09.007
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